Correspondence on ‘Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries’ by Sadek<i>et al</i>
Ilya Danelich(AstraZeneca (South Korea)), Gregory Oreste(AstraZeneca (United States)), James D. Williams(United States Fish and Wildlife Service), Veruska Di Sena(AstraZeneca (United States))
Cited by 0
Related Papers
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage
|JAMA Neurology|2024|88
Practical Management of Postoperative Atrial Fibrillation after Noncardiac Surgery
|Journal of the American College of Surgeons|2014|73
Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2015|55
Role of clinical pharmacists and pharmacy support personnel in transitions of care
|JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY|2020|40
Impact of the Pharmacy Practice Model Initiative on Clinical Pharmacy Specialist Practice
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2016|29